Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease

Hideo Hara, Alon Monsonego, Katsutoshi Yuasa, Kayo Adachi, Xiao Xiao, Shin'Ichi Takeda, Keikichi Takahashi, Howard L. Weiner, Takeshi Tabira

Research output: Contribution to journalArticlepeer-review

93 Scopus citations

Abstract

A new oral vaccine for Alzheimer's disease was developed using recombinant adeno-associated virus vector carrying Aβ cDNA (AAV/Aβ). Oral administration of the vaccine without adjuvant induced the expression and secretion of Aβ1-43 or Aβ1-21 in the epithelial cell layer of the intestine in amyloid precursor protein transgenic mice. Serum antibody levels were elevated for more than six months, while T cell proliferative responses to Aβ was not detected. Brain Aβ burden was significantly decreased compared to the control without inflammatory changes. This oral AAV/Aβ vaccine seems to be promising for prevention and treatment of Alzheimer's disease.

Original languageEnglish
Pages (from-to)483-488
Number of pages6
JournalJournal of Alzheimer's Disease
Volume6
Issue number5
DOIs
StatePublished - 1 Jan 2004
Externally publishedYes

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this